Eli Lilly axes 163 Dermira staffers, shutters Menlo Park site as it closes in around Dupixent rival lebrikizumab
Eli Lilly made it clear when it shelled out $1.1 billion for Dermira that lebrikizumab is really what it wanted to buy. One year …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
